Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes

Acta Pharmacologica Sinica, Published online: 25 May 2021; doi:10.1038/s41401-021-00692-7Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes

Source: Acta Pharmacologica Sinica - May 25, 2021 Category: Drugs & Pharmacology Authors: Ya-li Wu Ya-ru Xue Zi-tao Guo Zhen-dong Chen Xin-yu Ge Da-fang Zhong Xing-xing Diao Source Type: research